, /PRNewswire/ -- Insmed Incorporated (Nasdaq: ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that late-breaking data from the ARISE study of ARIKAYCE (amikacin liposome inhalation suspension) were presented at the American Thoracic Society (ATS) 2024 International Conference in . Data from ARISE evaluating patients with newly diagnosed or recurrent nontuberculous mycobacterial (NTM) lung infection caused by complex (MAC) who had not received antibiotics for their current infection were presented in an oral session and during the ATS Breaking News session "Clinical Trial Results in Pulmonary Medicine." "The inclusion of late-breaking ARISE data in both a plenary and in two oral sessions at ATS highlights the importance of these study results for the NTM community and the exciting potential for ARIKAYCE to reach a broader population of people living with MAC lung disease," said , M.
D., M.B.
A., Chief Medical Officer of Insmed. "Additionally, the ATS congress is an important opportunity for us to share our continued efforts to bring new therapies to patients with serious pulmonary diseases.
We are pleased to be presenting seven additional abstracts during the congress, including data on our investigational medicine brensocatib, as well as studies that deepen our understanding of bronchiectasis and pulmonary hypertension." As previously announced, data from ARISE demonstrated that the Quality o.
